health & beauty
3%
+
12,8%
olivier maubert
Global Head of Health & Beauty
Chief Innovation Officer
Chairman of Villa Blu by Robertet
The Health & Beauty Division delivered solid growth in 2025, albeit below its initial ambition, with revenue achieving 10.8% growth at constant scope and exchange rates.
Performance was impacted by a challenging global economic environment, particularly uncertainty linked to U.S. tariffs, as well as by our own organizational changes, whose benefits are expected to materialize mainly in 2026.
In terms of customers served, the geographical analysis reveals differing patterns. Europe was the strongest contributor, growing nearly 20%, driven by new developments with key customers in France and Germany, as well as the onboarding of new customers. Latin America also showed strong momentum (up 15%), supported by robust performance in Brazil through our distributor and continued growth in Mexico. North America grew modestly (up 7.3%), reflecting contrasting dynamics: strong growth from our local and most important agent (up 32%) following the improvement of our industrial capacities, partially offset by softer trends in legacy businesses. Asia experienced a significant slowdown, mainly due to reduced activity with our leading customer in Korea and weaker sales than expected in Japan; however, although still small, we are seeing early signs of recovery in strategic markets like Australia and India.
By product category, performance was mixed. Our melon-based super oxide dismutase (SOD) remained broadly stable, impacted by customer bankruptcies but supported by encouraging new business wins. Our hero product LIPOWHEAT™ WAS A STANDOUT, GROWING OVER 54%, following strong orders from key customers and the resolution of production issues. In contrast, Keranat™ declined. Emerging and smaller products showed very strong percentage growth, highlighting innovation-driven value-creation potential. The launch of Damasty™, our new technologically advanced ingredient for skin care radiance was a great success and shows high potential for development.
Looking ahead to 2026, we are confident in a strong acceleration after this transition year, targeting double digit growth compared with 2025. Our plan relies on reinforced scientific, branding and commercial capabilities.